Exact Sciences Cor (EXAS) 6.99 $EXAS
Exact Sciences Appoints Jeff Elliott to Lead Business Development & Strategy
PR Newswire - Fri Jun 03, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that Jeff Elliott, a former senior research analyst who covered the diagnostic and lab industries, will join the company as vice president, business development and strategy, effective June 20, 2016. In his new role, Mr. Elliott will oversee the identification and pursuit of strategic business opportunities, while also helping drive Cologuard's continued success.
EXAS: 6.99 (-0.17)
Exact Sciences to participate in three investor conferences during June
PR Newswire - Wed Jun 01, 3:15PM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in three investor conferences during June.
EXAS: 6.99 (-0.17)
Cologuard Available In-Network for Anthem Blue Cross and Blue Shield Members in Five Additional Midwest States
PR Newswire - Wed Jun 01, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed contract, Exact Sciences is now an in-network provider of Cologuard with Anthem Blue Cross and Blue Shield in the states of Indiana, Ohio, Kentucky, Missouri and Wisconsin.
EXAS: 6.99 (-0.17)
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
PR Newswire - Thu May 05, 3:15PM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 144,495 shares of common stock to 81 recently hired non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in equal annual installments over periods ranging from one to four years. The awards were approved by the independent Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the recently hired employees' entering into employment with the Company in accordance with NASDAQ Marketplace Rule 5635(c)(4). The Company is making this announcement as required by NASDAQ rules.
EXAS: 6.99 (-0.17)
Exact Sciences to participate in two investor conferences during May
PR Newswire - Thu May 05, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in two investor conferences during May.
EXAS: 6.99 (-0.17)
Downgrade Alert for Exact Sciences (EXAS)
Comtex SmarTrend(R) - Thu May 05, 3:52AM CDT
Exact Sciences (NASDAQ:EXAS) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $5.81 on volume of 3.3 million shares, above average daily volume of 1.8 million. Over the past year, Exact Sciences has traded in a range of $4.67 to $32.85 and closed yesterday at $5.81, 24% above that low. The 200-day and 50-day moving averages have moved 2.73% lower and 0.01% higher over the past week, respectively.
EXAS: 6.99 (-0.17)
Buy Exact Sciences Stock After a 72% Price Drop? 3 Things You Need to Know
Rich Smith, The Motley Fool - Motley Fool - Wed May 04, 12:40PM CDT
Shares of early cancer-detector Exact Sciences stock have lost 72% of their value over the past 52 weeks. This week alone, the stock shed 14% in the two days following its Q1 2016 earnings report -- a report that showed Exact Sciences beat...
EXAS: 6.99 (-0.17)
Exact Sciences reports 1Q loss
Automated Insights - Tue May 03, 4:05AM CDT
MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $47.5 million in its first quarter.
EXAS: 6.99 (-0.17)
Exact Sciences Completes 40,000 Cologuard Tests during First Quarter 2016
PR Newswire - Tue May 03, 4:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $14.8 million during its first quarter ended March 31, 2016, an increase of 244 percent compared to $4.3 million in the first quarter of 2015. During the first quarter of 2016, the company completed approximately 40,000 Cologuard tests, an increase of more than 260 percent compared to approximately 11,000 tests completed in the same quarter of 2015. The cumulative number of physicians ordering Cologuard since launch expanded to more than 32,000.
EXAS: 6.99 (-0.17)
Exact Sciences to host first-quarter 2016 results webcast and call
PR Newswire - Tue Apr 12, 4:30AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call on May 3, 2016, to discuss its first-quarter 2016 financial results.
EXAS: 6.99 (-0.17)
Is Exact Sciences Stock a Buy?
Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 26, 1:03PM CDT
Exact Sciences , maker of the noninvasive Cologuard colon cancer detection test, is very clearly a battleground stock. On one hand, Exact Sciences has a compelling growth story with a potentially game-changing detection tool. On the other hand, 26%...
ANTM: 131.52 (-2.23), EXAS: 6.99 (-0.17)
Could Cancer Deaths Really Be Eliminated for People Under the Age of 80 by 2050?
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 13, 8:12AM CDT
Image source: Pixabay. Cancer. It's potentially the scariest diagnosis a person can receive from their doctor, but it's something roughly 14 million people around the world will hear this year, according to the World Health Organization. In a...
ZIOP: 6.47 (-0.26), MYGN: 30.95 (-3.07), MRK: 56.81 (-0.37), XON: 25.27 (+0.14), EXAS: 6.99 (-0.17), BMY: 72.65 (-0.08)
3 Charts Show Why Exact Sciences May Still Be Too Risky
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 10, 6:21AM CST
SOURCE: EXACT SCIENCES. After reporting significant sales growth because of rising use of its colon cancer screening test, Exact Sciences offered up guidance for 2016 suggesting that its sales could more than double. Usually, a forecast for...
EXAS: 6.99 (-0.17)
Covered Call Alerts For Apple, Exact Sciences, American Express, FireEye and Gilead Sciences Released By InvestorsObserver
PR Newswire - Tue Mar 08, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, EXAS, AXP, FEYE and GILD.
FEYE: 15.81 (-0.77), AXP: 64.97 (-0.74), GILD: 84.45 (-1.32), EXAS: 6.99 (-0.17), AAPL: 98.83 (-0.82)
Why Exact Sciences Shares Jumped 12% Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 07, 3:37PM CST
Image source: Exact Sciences. What: After a post-EPS drop last month and a SEC filing late last week showing that one of its directors acquired additional shares, Exact Sciences ' share price climbed 12.8% today. So what: Despite...
MCD: 122.36 (-0.43), EXAS: 6.99 (-0.17)
How Risky Is Exact Sciences Stock?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 02, 9:16AM CST
Image source: Exact Sciences. The past year has been rough on Exact Sciences ' stock. After successfully navigating key product Cologuard through the regulatory and reimbursement maze, sales expectations were sky-high -- and so was the stock. At...
ANTM: 131.52 (-2.23), ILMN: 141.62 (-1.80), EXAS: 6.99 (-0.17)
Exact Sciences to host fourth-quarter, full-year 2015 results webcast and call
PR Newswire - Tue Feb 09, 4:00AM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call on Feb. 24, 2016, to discuss its fourth-quarter and full-year 2015 financial results.
EXAS: 6.99 (-0.17)
Exact Sciences to participate in Leerink Partners Global Healthcare Conference
PR Newswire - Mon Feb 01, 5:00AM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the Leerink Partners 5th Annual Global Healthcare Conference.
EXAS: 6.99 (-0.17)
Exact Sciences announces appointment of John A. Fallon, M.D., to company's board of directors
PR Newswire - Mon Jan 25, 7:43AM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that John A. Fallon, M.D., has joined the company's board of directors. Dr. Fallon brings more than 40 years of experience in health management, reimbursement, primary care and academic medicine to the board.
EXAS: 6.99 (-0.17)
A 10-Year Cancer Survival Rate Study From Japan Yields Interesting Results
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 23, 8:12AM CST
Image source: Flickr user Erik Soderstrom. Cancer. It may be the scariest diagnosis on the planet, and arguably the most worrisome six-letter word in the English language. According to estimates from the World Health Organization, cancer...
MRK: 56.81 (-0.37), EXAS: 6.99 (-0.17)
Exact Sciences Appoints Jeff Elliott to Lead Business Development & Strategy
PR Newswire - Fri Jun 03, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that Jeff Elliott, a former senior research analyst who covered the diagnostic and lab industries, will join the company as vice president, business development and strategy, effective June 20, 2016. In his new role, Mr. Elliott will oversee the identification and pursuit of strategic business opportunities, while also helping drive Cologuard's continued success.
EXAS: 6.99 (-0.17)
Exact Sciences to participate in three investor conferences during June
PR Newswire - Wed Jun 01, 3:15PM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in three investor conferences during June.
EXAS: 6.99 (-0.17)
Cologuard Available In-Network for Anthem Blue Cross and Blue Shield Members in Five Additional Midwest States
PR Newswire - Wed Jun 01, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed contract, Exact Sciences is now an in-network provider of Cologuard with Anthem Blue Cross and Blue Shield in the states of Indiana, Ohio, Kentucky, Missouri and Wisconsin.
EXAS: 6.99 (-0.17)
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
PR Newswire - Thu May 05, 3:15PM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 144,495 shares of common stock to 81 recently hired non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in equal annual installments over periods ranging from one to four years. The awards were approved by the independent Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the recently hired employees' entering into employment with the Company in accordance with NASDAQ Marketplace Rule 5635(c)(4). The Company is making this announcement as required by NASDAQ rules.
EXAS: 6.99 (-0.17)
Exact Sciences to participate in two investor conferences during May
PR Newswire - Thu May 05, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in two investor conferences during May.
EXAS: 6.99 (-0.17)
Downgrade Alert for Exact Sciences (EXAS)
Comtex SmarTrend(R) - Thu May 05, 3:52AM CDT
Exact Sciences (NASDAQ:EXAS) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $5.81 on volume of 3.3 million shares, above average daily volume of 1.8 million. Over the past year, Exact Sciences has traded in a range of $4.67 to $32.85 and closed yesterday at $5.81, 24% above that low. The 200-day and 50-day moving averages have moved 2.73% lower and 0.01% higher over the past week, respectively.
EXAS: 6.99 (-0.17)
Buy Exact Sciences Stock After a 72% Price Drop? 3 Things You Need to Know
Rich Smith, The Motley Fool - Motley Fool - Wed May 04, 12:40PM CDT
Shares of early cancer-detector Exact Sciences stock have lost 72% of their value over the past 52 weeks. This week alone, the stock shed 14% in the two days following its Q1 2016 earnings report -- a report that showed Exact Sciences beat...
EXAS: 6.99 (-0.17)
Exact Sciences reports 1Q loss
Automated Insights - Tue May 03, 4:05AM CDT
MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $47.5 million in its first quarter.
EXAS: 6.99 (-0.17)
Exact Sciences Completes 40,000 Cologuard Tests during First Quarter 2016
PR Newswire - Tue May 03, 4:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $14.8 million during its first quarter ended March 31, 2016, an increase of 244 percent compared to $4.3 million in the first quarter of 2015. During the first quarter of 2016, the company completed approximately 40,000 Cologuard tests, an increase of more than 260 percent compared to approximately 11,000 tests completed in the same quarter of 2015. The cumulative number of physicians ordering Cologuard since launch expanded to more than 32,000.
EXAS: 6.99 (-0.17)
Exact Sciences to host first-quarter 2016 results webcast and call
PR Newswire - Tue Apr 12, 4:30AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call on May 3, 2016, to discuss its first-quarter 2016 financial results.
EXAS: 6.99 (-0.17)
Is Exact Sciences Stock a Buy?
Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 26, 1:03PM CDT
Exact Sciences , maker of the noninvasive Cologuard colon cancer detection test, is very clearly a battleground stock. On one hand, Exact Sciences has a compelling growth story with a potentially game-changing detection tool. On the other hand, 26%...
ANTM: 131.52 (-2.23), EXAS: 6.99 (-0.17)
Could Cancer Deaths Really Be Eliminated for People Under the Age of 80 by 2050?
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 13, 8:12AM CDT
Image source: Pixabay. Cancer. It's potentially the scariest diagnosis a person can receive from their doctor, but it's something roughly 14 million people around the world will hear this year, according to the World Health Organization. In a...
ZIOP: 6.47 (-0.26), MYGN: 30.95 (-3.07), MRK: 56.81 (-0.37), XON: 25.27 (+0.14), EXAS: 6.99 (-0.17), BMY: 72.65 (-0.08)
3 Charts Show Why Exact Sciences May Still Be Too Risky
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 10, 6:21AM CST
SOURCE: EXACT SCIENCES. After reporting significant sales growth because of rising use of its colon cancer screening test, Exact Sciences offered up guidance for 2016 suggesting that its sales could more than double. Usually, a forecast for...
EXAS: 6.99 (-0.17)
Covered Call Alerts For Apple, Exact Sciences, American Express, FireEye and Gilead Sciences Released By InvestorsObserver
PR Newswire - Tue Mar 08, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, EXAS, AXP, FEYE and GILD.
FEYE: 15.81 (-0.77), AXP: 64.97 (-0.74), GILD: 84.45 (-1.32), EXAS: 6.99 (-0.17), AAPL: 98.83 (-0.82)
Why Exact Sciences Shares Jumped 12% Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 07, 3:37PM CST
Image source: Exact Sciences. What: After a post-EPS drop last month and a SEC filing late last week showing that one of its directors acquired additional shares, Exact Sciences ' share price climbed 12.8% today. So what: Despite...
MCD: 122.36 (-0.43), EXAS: 6.99 (-0.17)
How Risky Is Exact Sciences Stock?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 02, 9:16AM CST
Image source: Exact Sciences. The past year has been rough on Exact Sciences ' stock. After successfully navigating key product Cologuard through the regulatory and reimbursement maze, sales expectations were sky-high -- and so was the stock. At...
ANTM: 131.52 (-2.23), ILMN: 141.62 (-1.80), EXAS: 6.99 (-0.17)
Exact Sciences to host fourth-quarter, full-year 2015 results webcast and call
PR Newswire - Tue Feb 09, 4:00AM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call on Feb. 24, 2016, to discuss its fourth-quarter and full-year 2015 financial results.
EXAS: 6.99 (-0.17)
Exact Sciences to participate in Leerink Partners Global Healthcare Conference
PR Newswire - Mon Feb 01, 5:00AM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the Leerink Partners 5th Annual Global Healthcare Conference.
EXAS: 6.99 (-0.17)
Exact Sciences announces appointment of John A. Fallon, M.D., to company's board of directors
PR Newswire - Mon Jan 25, 7:43AM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that John A. Fallon, M.D., has joined the company's board of directors. Dr. Fallon brings more than 40 years of experience in health management, reimbursement, primary care and academic medicine to the board.
EXAS: 6.99 (-0.17)
A 10-Year Cancer Survival Rate Study From Japan Yields Interesting Results
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 23, 8:12AM CST
Image source: Flickr user Erik Soderstrom. Cancer. It may be the scariest diagnosis on the planet, and arguably the most worrisome six-letter word in the English language. According to estimates from the World Health Organization, cancer...
MRK: 56.81 (-0.37), EXAS: 6.99 (-0.17)
